New Research Report on Diabetes Therapeutics Market in India to 2018 by MarketResearchReports
Summary
Albany, NY, February 02, 2013 --( The report provides an in-depth analysis on oral anti-diabetics agents, insulin products and drivers and barriers that could significantly impact the overall anti-diabetes market during the forecast period.Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also discussed in the report.To Buy the copy of this Report visit: http://www.marketresearchreports.biz/analysis-details/diabetes-therapeutics-market-in-india-to-2018-rapid-uptake-of-dpp-iv-inhibitors-glp-1-agonists-and-expanding-insulin-segment-to-drive-growth GBI Researchs analysis revealed that the overall anti-diabetes market in India was worth $680.3m in 2011 and is projected to grow at a CAGR of 11.3% between 2011 and 2018 to reach $1,446m in 2018.To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis/160070 For More Information Kindly Contact: Hemendra Parmar State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Tel: +1-518-618-1030 sales@marketResearchReports.biz website: http://www.marketresearchreports.biz/ Blog: http://mrrbiz.blogspot.com/ Albany, NY, February 02, 2013 --( PR.com )-- GBI Research, the leading business intelligence provider, has released its latest research Diabetes Therapeutics Market in India to 2018 Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth, which provides insights into the India anti-diabetes market until 2018.High and growing diabetes population in the country, rising obese and geriatric population, and rapid market adoption of drugs from the classes such as Dipeptidyl Peptidase 4 (DPP-4) inhibitors, Glucagon-Like Peptide (GLP)-1, Sodium-Glucose Transport Proteins (SGLT-1) and others would drive the anti-diabetes market in the forecast period.The R&D product pipeline for DM, dominated by OAD agents, consists of around 200 molecules at various stages of clinical development.